Arovella presents poster at AACR Annual Meeting
Highlights:
Arovella presents its recent CLDN18.2 pre-clinical data at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
Data shows CLDN18.2 CAR-iNKT cells effectively kill CLDN18.2-positive pancreatic cancer and gastric cancer cells in in vitro studies
MELBOURNE, AUSTRALIA 20 April 2026: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that today it will be presenting a poster describing its CAR-iNKT cell therapy targeting CLDN18.2-positive cancers at the American Association for Cancer Research (AACR) Annual Meeting in San Diego. The AACR annual meeting is a focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine
The poster, titled Allogeneic CAR-iNKT cell therapy targeting CLDN18.2-positive gastric and pancreatic cancers describes in detail the data that was released in Arovella’s announcement on 1 April 2026, CLDN18.2 CAR iNKT Cell Preclinical Data Update.
Arovella CEO and Managing Director, Dr Michael Baker, commented: “We are delighted to have been accepted to present our CLDN18.2-CAR-iNKT cell data at the AACR conference. It is exciting data and highlights the impressive performance of the CLDN18.2 CAR and the additional benefit of incorporating Arovella’s cytokine armouring technology, IL-12-TM. We are looking forward to generating additional data in due course.”
A recent video with Dr Baker’s explanation of the data can be viewed here.
